Diagnostic imaging, outpatient, and cancer care services provider Affidea Group is teaming with Belgian software company Icometrix to improve care for patients with multiple sclerosis (MS) and other neurological disorders using artificial intelligence (AI).
Icometrix's icobrain AI software is designed to help radiologists and neurologists quantify and track different brain abnormalities on MRI scans. Information is presented in a report that includes healthy control data to aid in the interpretation and communication of results.
Affidea will implement a new AI tool, known as icobrainms, to monitor disease progression and help assess MS patients to improve their treatment and follow-up care.
The pilot program will launch in Italy, Portugal, Switzerland, and Serbia.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
